People with a particular genetic variation have a reduced response to the antiplatelet drug clopidogrel, a study has found. The research could expedite the use of pharmacogenetic testing to enable antiplatelet therapy to be tailored to each patient. Patients with the variant who ...
Please Login to read the full article.
